#1 Clinical Trials Search in Europe

Risankizumab

This article delves into the use of Risankizumab, a promising drug being studied in clinical trials for various conditions, including Crohn’s disease, plaque psoriasis, and in healthy volunteers. These trials aim to evaluate the drug’s safety, effectiveness, and how it moves through the body when administered in different ways.

Table of Contents

Introduction

Risankizumab is a medication that has been the subject of several clinical trials to evaluate its effectiveness, safety, and how it behaves in the body. This article aims to provide patients with a comprehensive overview of risankizumab, including its uses, administration methods, and what researchers are studying about it.[1][2][3][4][5]

What is Risankizumab?

Risankizumab, also known by the brand name SKYRIZI or the research code ABBV-066, is a medication being studied for various medical conditions. While the specific conditions it treats are not explicitly mentioned in the provided clinical trial data, risankizumab is typically used to treat certain autoimmune disorders.[1][2][3]

How is Risankizumab Administered?

Risankizumab can be administered in several ways, according to the clinical trials:

  • Subcutaneous (SC) injection: This involves injecting the medication just under the skin. It can be done using:
    • A prefilled syringe (PFS)
    • An auto-injector (AI)
    • An on-body delivery system (OBDS)
  • Intravenous (IV) infusion: This method involves administering the medication directly into a vein.

The choice of administration method may depend on factors such as the specific treatment plan, dosage, and patient preference.[1][2][3][4][5]

Clinical Studies on Risankizumab

The clinical trials described in the provided information focus on several aspects of risankizumab:

  • Pharmacokinetics: These studies aim to understand how the body processes the drug, including how it’s absorbed, distributed, and eliminated.[1][2][3]
  • Bioavailability: Researchers are comparing how much of the drug becomes available in the body when administered through different methods or formulations.[4][5]
  • Safety and tolerability: All studies are monitoring for potential side effects and how well participants tolerate the medication.[1][2][3][4][5]

It’s important to note that these studies are being conducted on healthy volunteers, which is a common practice in early-phase clinical trials to establish the basic properties and safety profile of a drug before testing it in patients with specific conditions.

Safety and Side Effects

All of the clinical trials mentioned are closely monitoring for adverse events (AEs). An adverse event is any undesirable experience associated with the use of a medical product in a patient. The researchers assess whether these events are related to the study drug.[1][2][3][4][5]

The studies are also looking at the development of anti-drug antibodies (ADAs). These are antibodies that the body might produce in response to the medication, which could potentially affect its effectiveness or safety.[3][4][5]

Pharmacokinetics of Risankizumab

The clinical trials are measuring several pharmacokinetic parameters to understand how risankizumab behaves in the body:

  • Maximum concentration (Cmax): The highest concentration of the drug in the blood after administration.
  • Time to maximum concentration (Tmax): How long it takes to reach the maximum concentration.
  • Area under the curve (AUC): A measure of the total exposure to the drug over time.
  • Elimination rate and half-life: How quickly the body eliminates the drug.
  • Clearance: The volume of blood cleared of the drug per unit time.

These measurements help researchers understand how the drug is processed by the body and can inform dosing recommendations.[1][2][3][4][5]

Frequently Asked Questions

What conditions does risankizumab treat?

While the provided clinical trial information doesn’t specify the conditions risankizumab treats, it’s typically used for certain autoimmune disorders. For accurate information about its approved uses, consult with a healthcare provider or refer to the official drug information.

How long do the effects of risankizumab last?

The clinical trials are studying the drug’s behavior in the body for up to 140 days after administration. However, the duration of the drug’s effects can vary depending on factors such as dosage and individual patient characteristics. Your healthcare provider can provide more specific information based on your treatment plan.

Are there any long-term side effects of risankizumab?

The clinical trials described are primarily focused on short-term effects and how the body processes the drug. Long-term side effects would typically be studied in larger, longer-duration clinical trials or post-marketing surveillance. Always discuss potential side effects with your healthcare provider.

Summary

Aspect Details
Drug Name Risankizumab (SKYRIZI, ABBV-066)
Administration Methods Subcutaneous injection, Intravenous infusion
Key Study Objectives Pharmacokinetics, Bioavailability, Safety, Tolerability
Study Participants Healthy volunteers
Safety Monitoring Adverse events, Anti-drug antibodies
Pharmacokinetic Measures Cmax, Tmax, AUC, Elimination rate, Half-life, Clearance

Glossary

  • Pharmacokinetics – The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion
  • Bioavailability – The proportion of a drug that enters the circulation when introduced into the body and so is able to have an active effect
  • Subcutaneous – Beneath the skin
  • Intravenous – Into a vein
  • Adverse event – Any undesirable experience associated with the use of a medical product in a patient
  • Anti-drug antibodies – Antibodies produced by the body against a therapeutic drug

Trial sources

  • [1]: https://clinicaltrials.gov/study/NCT05274100
  • [2]: https://clinicaltrials.gov/study/NCT06487572
  • [3]: https://clinicaltrials.gov/study/NCT05268068
  • [4]: https://clinicaltrials.gov/study/NCT05283681
  • [5]: https://clinicaltrials.gov/study/NCT05283694
Aspect Details
Drug Name Risankizumab (also known as ABBV-066, SKYRIZI)
Conditions Studied Crohn’s Disease, Plaque Psoriasis, Healthy Volunteers
Administration Methods Intravenous (IV) Infusion, Subcutaneous (SC) Injection
Age Groups Adults, Pediatric (2 to <18 years)
Primary Outcomes Measured Safety (Adverse Events), Pharmacokinetics, Clinical Remission, Endoscopic Response
Study Durations Range from 140 days to 204 weeks
Key Assessments Blood tests, Endoscopic examinations, Patient-reported outcomes

FAQ

  • What is Risankizumab? Risankizumab is a drug that is approved for treating conditions like plaque psoriasis in adults. It is currently being studied for use in other conditions and in pediatric populations.
  • What conditions are being studied with Risankizumab in these clinical trials? The clinical trials are studying Risankizumab for conditions such as Crohn's disease in both adults and children, plaque psoriasis in children, and its effects in healthy volunteers.
  • How is Risankizumab administered in these trials? Risankizumab is administered in various ways depending on the trial, including intravenous (IV) infusion and subcutaneous (SC) injection. Some trials are comparing different methods of administration.
  • What are the main goals of these clinical trials? The main goals include assessing the safety and effectiveness of Risankizumab, studying how it moves through the body (pharmacokinetics), and evaluating different dosing regimens and formulations.
  • How long do these clinical trials typically last? The duration of the trials varies, with some lasting up to 140 days for short-term studies, while others extend to 204 weeks or more for long-term safety and efficacy evaluation.

Ongoing Clinical Trials on Risankizumab

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Subcutaneous (SC) Injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Intravenous (IV) Infusion: A method of administering medication directly into a vein using a needle or tube.
  • Adverse Event (AE): Any undesirable experience associated with the use of a medical product in a patient.
  • Crohn's Disease: A type of inflammatory bowel disease that causes inflammation of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.
  • Plaque Psoriasis: A condition causing skin cells to build up and form scales and itchy, dry patches.
  • Anti-drug Antibody (ADA): Antibodies that develop in response to a therapeutic drug, which can potentially reduce the drug's effectiveness.
  • Endoscopic Response: An improvement in the appearance of the intestinal lining as viewed through an endoscope, often used as a measure of treatment effectiveness in Crohn's disease.
  • Pediatric Crohn's Disease Activity Index (PCDAI): A tool used to measure the severity of Crohn's disease in children, considering factors like abdominal pain, stool frequency, and overall well-being.